References
1. Hommes DW, Peppelenbosch MP, Van Deventer SJH. Mitogen activated
protein (MAP) kinase signal transduction pathways and novel
anti-inflammatory targets. Gut. 2003;52:144–51.
2. Dominguez C, Powers DA, Tamayo N. p38 MAP kinase inhibitors: many are
made, but few are chosen. Curr Opin Drug Discov Devel. 2005;8:421–30.
3. Kaminska B. MAPK signalling pathways as molecular targets for
anti-inflammatory therapy—from molecular mechanisms to therapeutic
benefits. Biochim Biophys Acta (BBA)-Proteins Proteomics.
2005;1754:253–62.
4. Lee JC, Kumar S, Griswold DE, Underwood DC, Votta BJ, Adams JL.
Inhibition of p38 MAP kinase as a therapeutic strategy.
Immunopharmacology. 2000;47:185–201.
5. Collamer AN, Guerrero KT, Henning JS, Battafarano DF. Psoriatic skin
lesions induced by tumor necrosis factor antagonist therapy: a
literature review and potential mechanisms of action. Arthritis Care Res
Off J Am Coll Rheumatol. 2008;59:996–1001.
6. Lee JK, Kim N-J. Recent advances in the inhibition of p38 MAPK as a
potential strategy for the treatment of Alzheimer’s disease. Molecules.
2017;22:1287.
7. Zarubin T, Jiahuai HAN. Activation and signaling of the p38 MAP
kinase pathway. Cell Res. 2005;15:11.
8. Schindler JF, Monahan JB, Smith WG. p38 pathway kinases as
anti-inflammatory drug targets. J Dent Res. 2007;86:800–11.
9. Kuma Y, Sabio G, Bain J, Shpiro N, Márquez R, Cuenda A. BIRB796
inhibits all p38 MAPK isoforms in vitro and in vivo. J Biol Chem.
2005;280:19472–9.
10. Cuenda A, Rousseau S. p38 MAP-kinases pathway regulation, function
and role in human diseases. Biochim Biophys Acta (BBA)-Molecular Cell
Res. 2007;1773:1358–75.
11. Lu Y-C, Yeh W-C, Ohashi PS. LPS/TLR4 signal transduction pathway.
Cytokine. 2008;42:145–51.
12. Jerala R. Structural biology of the LPS recognition. Int J Med
Microbiol. 2007;297:353–63.
13. Lee MR, Dominguez C. Map kinase p38inhibitors: Clinical results and
an intimate look at their interactions with p38α protein. Curr Med Chem.
2005;12:2979–94.
14. Kong T-T, Zhang C-M, Liu Z-P. Recent developments of p38α MAP kinase
inhibitors as antiinflammatory agents based on the imidazole scaffolds.
Curr Med Chem. 2013;20:1997–2016.
15. Khorasanizadeh MH, Eskian M, Gelfand EW, Rezaei N. Mitogen-activated
protein kinases as therapeutic targets for asthma. Pharmacology and
Therapeutics. 2017;174:112–26.
16. Mihara K, Almansa C, Smeets RL, Loomans EEMG, Dulos J, Vink PMF, et
al. A potent and selective p38 inhibitor protects against bone damage in
murine collagen-induced arthritis: A comparison with neutralization of
mouse TNFα. Br J Pharmacol. 2008;154:153–64.
17. Sarvetnick N, Fox HS. Interferon-gamma and the sexual dimorphism of
autoimmunity. Mol Biol Med. 1990;7:323–31.
18. Lockshin MD. Sex differences in autoimmune disease. Handb Syst
autoimmune Dis. 2005;4:3–10.
19. Fairweather D, Frisancho-Kiss S, Rose NR. Sex differences in
autoimmune disease from a pathological perspective. Am J Pathol.
2008;173:600–9.
20. Singh BN. Effects of food on clinical pharmacokinetics. Clin
Pharmacokinet. 1999;37:213–55.
21. Petrovsky N, McNair P, Harrison LC. Diurnal rhythms of
pro-inflammatory cytokines: regulation by plasma cortisol and
therapeutic implications. Cytokine. 1998;10:307–12.
22. Amacher DE. Serum transaminase elevations as indicators of hepatic
injury following the administration of drugs. Regul Toxicol Pharmacol.
1998;27:119–30.
23. Harris HW, Johnson JA, Wigmore SJ. Endogenous lipoproteins impact
the response to endotoxin in humans. Crit Care Med. 2002;30:23–31.
24. Mohrschladt MF, Weverling-Rijnsburger AWE, De Man F, Stoeken D-J,
Sturk A, Smelt AHM, et al. Hyperlipoproteinemia affects cytokine
production in whole blood samples ex vivo. The influence of
lipid-lowering therapy. Atherosclerosis. 2000;148:413–9.
25. Aulock S von, Deininger S, Draing C, Gueinzius K, Dehus O, Hermann
C. Gender difference in cytokine secretion on immune stimulation with
LPS and LTA. J Interf cytokine Res. 2006;26:887–92.
26. Asai K, Hiki N, Mimura Y, Ogawa T, Unou K, Kaminishi M. Gender
differences in cytokine secretion by human peripheral blood mononuclear
cells: role of estrogen in modulating LPS-induced cytokine secretion in
an ex vivo septic model. Shock. 2001;16:340–3.